Pacira Pharmaceuticals Stock
Price
Target price
€19.30
€19.30
0.000%
-
0.000%
€30.74
04.07.25 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
There is no change in the price for Pacira Pharmaceuticals today.
We see a rather positive sentiment for Pacira Pharmaceuticals with 13 Buy predictions and 1 Sell predictions.
As a result the target price of 30 € shows a very positive potential of 55.44% compared to the current price of 19.3 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | -2.030% | -15.351% | -2.030% | 4.324% | -64.259% | -58.043% |
| Rockwell Medical Inc. | -0.150% | 1.711% | -21.930% | -57.201% | -66.096% | -43.042% | -96.323% |
| Twist Bioscience Corp | -0.310% | 4.886% | 20.735% | -26.366% | -29.587% | -9.193% | -21.845% |
| Vericel Corp. | 0.000% | -0.571% | -3.867% | -13.861% | -36.147% | 41.005% | 159.798% |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $32.00 to $30.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at HC Wainwright from $48.00 to $65.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
